A new paper was published in Volume 13 of Oncoscience on February 6, 2026, titled "Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety ...

The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for ...

Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.

AutoChamber™ and AutoBMD™ AI solutions will soon be available on Precision Imaging Network, with AI-CVD® planned next.

NEW YORK – The US Food and Drug Administration has accepted Roche subsidiary Genentech's new drug application for giredestrant in combination with the mTOR inhibitor Afinitor (everolimus) for estrogen ...

The organization presented data aggregated from multiple clinical trials to explore ctDNA's potential as a surrogate endpoint predictive of treatment benefit in lung and other cancers.

The FDA's top drug regulator indicated in her first address to staff that she will scrutinize antidepressants and shots used to protect babies from RSV ...

A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in ...

ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle ...

GRAIL (GRAL) stock plunges after NHS-Galleri trial miss for Galleri cancer test, which was added to the Hims & Hers (HIMS) platform earlier this month. Read more here.

NEW ORLEANS , LA, UNITED STATES, January 29, 2026 /EINPresswire.com/ -- HeartLung Corporation announced today that ...

AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...